Keya Medical
AI for Smarter Healthcare
contact
Diagnostic Solutions
Treatment Solutions
Solution Suites
Cardiology
Neurology
Pulmonology
Pathology
General Surgery
Cardio Suite
Stroke Suite
Diagnostic Solutions
Cardiology
Neurology
Pulmonology
Pathology
Treatment Solutions
Vascular Surgery
General Surgery
Solutions Suites
Cardio Suite
Stroke Suite
DeepVessel® FFR
DeepVessel FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
Enabling better diagnosis and treatment of patients with coronary artery disease.
Comprehensive R&D Pipeline Solution Suites
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment maintenance.
Keya Medical: world’s leading AI medical device company
Keya Medical is dedicated to the development and commercialization of deep learning-based medical devices for disease diagnosis and treatment with a goal to revolutionize the medical device industry.
Keya Medical has developed solutions for specialties including cardiology, radiology, neurology, pathology, and surgery. Since 2016, we have collaborated with 728 hospitals to improve care delivery on a global scale.
Latest News
Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
Calcium Scoring from Coronary CT Angiography Using Deep Learning
Coronary Artery Calcium (CAC) scores have become increasingly important in assessing risk for coronary artery disease. Although non-contrast CT scans are typically used for CAC scoring, calculating CAC scores from CTAs directly could add further value to CTAs as a...
2021 ACC AHA Guideline Promotes Shared Decision-Making
The 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain was released on 28 October 2021. This report represents years of work by the Joint Committee on Clinical Practice Guidelines to define protocols and algorithms based on the evidence.
Beijing Anzhen Hospital Successfully Implements DeepVessel FFR
On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital.
Let’s transform the future of healthcare together
Products
DeepVessel FFR
CuraRad-ICH
Solutions
All Solutions
Diagnostic Solutions
Treatment Solutions
Solution Suites
